bluuebunny/crossref_metadata_2025 huggingface dataset:
supplemental tables and figures from Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
Authors: Yu Helena A. , Suzawa Ken , Jordan Emmet , Zehir Ahmet , Ni Ai , Kim Ryan , Kris Mark G. , Hellmann Matthew D. , Li Bob T. , Somwar Romel , Solit David B. , Berger Michael F. , Arcila Maria , Riely Gregory J. , Ladanyi Marc
Published: April 2023

Supplemental table 1: Paired biopsies in 38 patients with site of biopsy and EGFR mutations identified Supplementary Table 2: Alterations detected in 38 patients that had paired samples assessed by IMPACT prior and upon resistance to EGFR-TKI therapy Supplemental Figure 1: Relative expression of phosphoryrated proteins in transient cell line model. 293T cells were transiently transfected with pcDNA3 Flag-mTOR (WT, E2419K, S1483F, S2215F), vector control, or HA-S6K1. Thirty-six hours after the transfection, cells were serum starved overnight and subsequently nutrition starved in PBS for 1 hour. Lysates were subjected to immunoblotting. Band intensities were quantified using ImageJ software, and data are representative of two independent experiments (mean {plus minus} SE). ***p<0.001, compared to the respective WT+S6K group. Supplemental Figure 2: Cell growth and viability of isogenic PC9-mTOR cell line model with erlotinib treatment. PC9-mTOR cell lines were treated with erlotinib for 96 hours. Each experiment was assayed in six-replicate determinations and data are representative of three independent experiments (mean {plus minus} SE). Supplemental Figure 3: Cell growth and viability of isogenic PC9-mTOR cell line model with AZD8055 treatment. PC9-mTOR cell lines were treated with AZD8055 for 96 hours. Each experiment was assayed in six-replicate determinations and data are representative of three independent experiments (mean {plus minus} SE). Supplemental Figure 4: Changes of body weight PC9-mTOR E2419K cells were implanted subcutaneously into the flank of athymic nude mice. Once tumors reached approximately 100 mm3 , mice were treated with vehicle, 25 mg/kg erlotinib, 20 mg/kg AZD8055, or a combination of 25 mg/kg erlotinib and 20 mg/kg AZD8055 daily. Body weight was determined on the indicated days after the onset of treatment. Data represent mean {plus minus} SE (n = 5).
Supplemental Figure S4 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
Authors: Liu Liqin , Lam Chia-Ying K. , Long Vatana , Widjaja Lusiana , Yang Yinhua , Li Hua , Jin Linda , Burke Steve , Gorlatov Sergey , Brown Jennifer , Alderson Ralph , Lewis Margaret D. , Nordstrom Jeffrey L. , Koenig Scott , Moore Paul A. , Johnson Syd , Bonvini Ezio
Published: April 2023

MGD011 induced malignant B-cell depletion and endogenous T-cell activation in PBMCs from additional CLL patient sample
Supplemental Figure S2 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
Authors: Liu Liqin , Lam Chia-Ying K. , Long Vatana , Widjaja Lusiana , Yang Yinhua , Li Hua , Jin Linda , Burke Steve , Gorlatov Sergey , Brown Jennifer , Alderson Ralph , Lewis Margaret D. , Nordstrom Jeffrey L. , Koenig Scott , Moore Paul A. , Johnson Syd , Bonvini Ezio
Published: April 2023

MGD011 demonstrated concentration-dependent binding on human and cynomolgus monkey CD20 B cells and CD4, CD8 T cells
Table S3 from Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Authors: Goldberg Sarah B. , Narayan Azeet , Kole Adam J. , Decker Roy H. , Teysir Jimmitti , Carriero Nicholas J. , Lee Angela , Nemati Roxanne , Nath Sameer K. , Mane Shrikant M. , Deng Yanhong , Sukumar Nitin , Zelterman Daniel , Boffa Daniel J. , Politi Katerina , Gettinger Scott N. , Wilson Lynn D. , Herbst Roy S. , Patel Abhijit A.
Published: April 2023

Detailed Individual Characteristics of 49 Enrolled Patients
Supplementary Methods, Figures S1-6, Tables S1,2,4,6-8 from Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Authors: Goldberg Sarah B. , Narayan Azeet , Kole Adam J. , Decker Roy H. , Teysir Jimmitti , Carriero Nicholas J. , Lee Angela , Nemati Roxanne , Nath Sameer K. , Mane Shrikant M. , Deng Yanhong , Sukumar Nitin , Zelterman Daniel , Boffa Daniel J. , Politi Katerina , Gettinger Scott N. , Wilson Lynn D. , Herbst Roy S. , Patel Abhijit A.
Published: April 2023

Supplementary Materials
Figure S1 from The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis
Authors: Deel Michael D. , Slemmons Katherine K. , Hinson Ashley R. , Genadry Katia C. , Burgess Breanne A. , Crose Lisa E.S. , Kuprasertkul Nina , Oristian Kristianne M. , Bentley Rex C. , Linardic Corinne M.
Published: April 2023

Standards used for TAZ and YAP IHC scoring in human TMAs.
Supplementary Table from Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer
Authors: Chen Chun-Han , Changou Chun A. , Hsieh Tsung-Han , Lee Yu-Ching , Chu Cheng-Ying , Hsu Kai-Cheng , Wang Hao-Ching , Lin Yu-Chen , Lo Yan-Ni , Liu Yun-Ru , Liou Jing-Ping , Yen Yun
Published: April 2023

Supplementary Table S1. In vitro inhibitory effects of MPT0L145 on a panel of lipid kinases. Supplementary Table S2. Binding kinetics and affinity of MPT0L145 to wildtype and mutant PIK3C3.
Supplementary Methods, Supplementary Figures 1-5, Supplementary Tables 1-2 from Downregulation of DNMT3A by miR-708-5p Inhibits Lung Cancer Stem Cell–like Phenotypes through Repressing Wnt/β-catenin Signaling
Authors: Liu Tianchi , Wu Xiaoping , Chen Tong , Luo Zewei , Hu Xiaohua
Published: April 2023

Figure S1. MiR-708-5p regulates stem cell-like properties in NSCLC cells; Figure S2. DNMT3A is a direct target of miR-708-5p; Figure S3. (A) Schematics of DNMT3A synonymous mutation at the binding sites of miR-708-5p in the wide type coding DNA sequence (CDS) of DNMT3B; Figure S4. qRT-PCR (A) and western blot (B) analysis the expression of β-catenin in miR-708-5p-transfected cells compared with the corresponding control ones in A549, Calu-3 and 95D cells; Figure S5. (A) Comparison of relative expression of miR-708-5p between two groups of adenocarcinomous patients in TCGA cohort, classified by molecular subtype based on EGFR mutation, ALK fusion, TP53 mutation and KRAS mutation, respectively; Table S1: The clinicopathological information for PQG samples; Table S2: The clinicopathological information for TCGA lung cancer dataset containing miRNA-seq data [1].
Supplementary Table 3 from Vitamin D–Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription
Authors: Huang Yu-Fang , Wu Yi-Hui , Cheng Wen-Fang , Peng Shu-Ling , Shen Wan-Lin , Chou Cheng-Yang
Published: April 2023

Immunohistochemistrical DBP expression and patient demographics (n=245).
Supplementary Figure 3 from Vitamin D–Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription
Authors: Huang Yu-Fang , Wu Yi-Hui , Cheng Wen-Fang , Peng Shu-Ling , Shen Wan-Lin , Chou Cheng-Yang
Published: April 2023

Overall survival and progression-free survival. Kaplan-Meier curves stratified by (A) ascitic DBP, and (B) serum DBP tested by log rank test
Supplementary Table S2 from Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the IDH1 Mutation Status
Authors: Uckermann Ortrud , Juratli Tareq A. , Galli Roberta , Conde Marina , Wiedemuth Ralf , Krex Dietmar , Geiger Kathrin , Temme Achim , Schackert Gabriele , Koch Edmund , Steiner Gerald , Kirsch Matthias
Published: April 2023

Fresh, unfixed biopsies of human brain tumor samples.
Supplementary Table S1 from Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the IDH1 Mutation Status
Authors: Uckermann Ortrud , Juratli Tareq A. , Galli Roberta , Conde Marina , Wiedemuth Ralf , Krex Dietmar , Geiger Kathrin , Temme Achim , Schackert Gabriele , Koch Edmund , Steiner Gerald , Kirsch Matthias
Published: April 2023

Cryosections of human brain tumor samples
Supplementary Figure S4 from Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the IDH1 Mutation Status
Authors: Uckermann Ortrud , Juratli Tareq A. , Galli Roberta , Conde Marina , Wiedemuth Ralf , Krex Dietmar , Geiger Kathrin , Temme Achim , Schackert Gabriele , Koch Edmund , Steiner Gerald , Kirsch Matthias
Published: April 2023

Comparison of FT-IR spectra and ATR FT-IR spectra of brain tissue.
Supplemental material from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
Authors: Ribba Benjamin , Boetsch Christophe , Nayak Tapan , Grimm Hans Peter , Charo Jehad , Evers Stefan , Klein Christian , Tessier Jean , Charoin Jean Eric , Phipps Alex , Pisa Pavel , Teichgräber Volker
Published: April 2023

Supplemental material
Supp Figure S9 from A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers
Authors: Zhu Shoumin , Chen Zheng , Wang Lihong , Peng Dunfa , Belkhiri Abbes , Lockhart A. Craig , El-Rifai Wael
Published: April 2023

Supp Figure S9
Supp Figure S8 from A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers
Authors: Zhu Shoumin , Chen Zheng , Wang Lihong , Peng Dunfa , Belkhiri Abbes , Lockhart A. Craig , El-Rifai Wael
Published: April 2023

Supp Figure S8
Supplementary Table S5 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
Authors: Mason Nicola J. , Gnanandarajah Josephine S. , Engiles Julie B. , Gray Falon , Laughlin Danielle , Gaurnier-Hausser Anita , Wallecha Anu , Huebner Margie , Paterson Yvonne
Published: April 2023

Comparison between the baseline characteristics of ADXS31-164 treated and historical control groups.
Supplementary Table S4 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
Authors: Mason Nicola J. , Gnanandarajah Josephine S. , Engiles Julie B. , Gray Falon , Laughlin Danielle , Gaurnier-Hausser Anita , Wallecha Anu , Huebner Margie , Paterson Yvonne
Published: April 2023

Signalment and primary tumor characteristics of dogs in the historical control group.
Supp Figure S11 from A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers
Authors: Zhu Shoumin , Chen Zheng , Wang Lihong , Peng Dunfa , Belkhiri Abbes , Lockhart A. Craig , El-Rifai Wael
Published: April 2023

Supp Figure S11
Supplementary Table S3 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
Authors: Mason Nicola J. , Gnanandarajah Josephine S. , Engiles Julie B. , Gray Falon , Laughlin Danielle , Gaurnier-Hausser Anita , Wallecha Anu , Huebner Margie , Paterson Yvonne
Published: April 2023

ELISpot analysis of IFN-γ responses to the intracellular and extracellular domains of HER2/neu before and after ADXS31-164 administration.
Supplementary Table 1 from Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation
Authors: Takagi Satoshi , Tsukamoto Shokichi , Park Jihye , Johnson Kelly E. , Kawano Yawara , Moschetta Michele , Liu Chia-Jen , Mishima Yuji , Kokubun Katsutoshi , Manier Salomon , Salem Karma Z. , Huynh Daisy , Sacco Antonio , Forward Jodi , Roccaro Aldo M. , Battinelli Elisabeth M. , Ghobrial Irene M.
Published: April 2023

Clinical information of patients with MGUS, SMM, or MM.
Fig S5 from Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation
Authors: Takagi Satoshi , Tsukamoto Shokichi , Park Jihye , Johnson Kelly E. , Kawano Yawara , Moschetta Michele , Liu Chia-Jen , Mishima Yuji , Kokubun Katsutoshi , Manier Salomon , Salem Karma Z. , Huynh Daisy , Sacco Antonio , Forward Jodi , Roccaro Aldo M. , Battinelli Elisabeth M. , Ghobrial Irene M.
Published: April 2023

Tumor-interacting platelets could be removed by wash process completely.
Fig S2 from Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation
Authors: Takagi Satoshi , Tsukamoto Shokichi , Park Jihye , Johnson Kelly E. , Kawano Yawara , Moschetta Michele , Liu Chia-Jen , Mishima Yuji , Kokubun Katsutoshi , Manier Salomon , Salem Karma Z. , Huynh Daisy , Sacco Antonio , Forward Jodi , Roccaro Aldo M. , Battinelli Elisabeth M. , Ghobrial Irene M.
Published: April 2023

Murine platelets enhance proliferation rate of murine multiple myeloma cells in vitro.
Supplementary legend from Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
Authors: Canale Matteo , Petracci Elisabetta , Delmonte Angelo , Chiadini Elisa , Dazzi Claudio , Papi Maximilian , Capelli Laura , Casanova Claudia , De Luigi Nicoletta , Mariotti Marita , Gamboni Alessandro , Chiari Rita , Bennati Chiara , Calistri Daniele , Ludovini Vienna , Crinò Lucio , Amadori Dino , Ulivi Paola
Published: April 2023

Supplementary legend
Figure S1-S6 from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer
Authors: Haynes Jennifer , McKee Trevor D. , Haller Andrew , Wang Yadong , Leung Cherry , Gendoo Deena M.A. , Lima-Fernandes Evelyne , Kreso Antonija , Wolman Robin , Szentgyorgyi Eva , Vines Douglass C. , Haibe-Kains Benjamin , Wouters Bradly G. , Metser Ur , Jaffray David A. , Smith Myles , O'Brien Catherine A.
Published: April 2023

Supplementary Figure S1. Hypoxia increases stem gene expression and stabilizes HIF proteins. Supplementary Figure S2. Chemotherapy enriches for colorectal C-IC markers and increases expression of Wnt and HIF targets. Supplementary Figure S3. Growth of colorectal cancer PDXs shown in Figure 4. Supplementary Figure S4. Hypoxic fraction in a panel of colorectal cancer PDX models. Supplementary Figure S5. Growth of colorectal cancer PDXs shown in Figure 5. Supplementary Figure S6. Hypoxia gene sets are prognostic for clinical outcome of colon cancer patients.
Supplementary Date (For Publication) from Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression
Authors: Nesbitt Heather , Byrne Niall M. , Williams S. Nicole , Ming Louise , Worthington Jenny , Errington Rachel J. , Patterson Laurence H. , Smith Paul J. , McKeown Stephanie R. , McKenna Declan J.
Published: April 2023

Supplementary Data contains Supplementary Table S1: Primer Sequences Supplementary Figure S1: Gene Layout on RealTime Ready custom 96 well panel Supplementary Figure S2: OCT1002 targets 22Rv1 and PC3 in hypoxic conditions Supplementary Figure S3: OCT1002 induces apoptosis in LNCAP-luc spheroids Supplementary Figure S4: Effect of bicalutamide and OCT1002 on tumor growth in 22Rv1 xenografts Supplementary Figure S5: Stereological analysis of microvessels in LNCaP tumors grown in window chambers Supplementary Figure S6: Effect of bicalutamide on oxygenation of 22Rv1 xenografts
Supplementary Figure S2 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo
Authors: Laszlo Viktoria , Valko Zsuzsanna , Kovacs Ildiko , Ozsvar Judit , Hoda Mir Alireza , Klikovits Thomas , Lakatos Dora , Czirok Andras , Garay Tamas , Stiglbauer Alexander , Helbich Thomas H. , Gröger Marion , Tovari Jozsef , Klepetko Walter , Pirker Christine , Grusch Michael , Berger Walter , Hilberg Frank , Hegedus Balazs , Dome Balazs
Published: April 2023

Expression of target RTKs of nintedanib in the P31 and SPC111 cells
Supplementary Methods and Figure legends from FAM198B Is Associated with Prolonged Survival and Inhibits Metastasis in Lung Adenocarcinoma via Blockage of ERK-Mediated MMP-1 Expression
Authors: Hsu Chia-Ying , Chang Gee-Chen , Chen Yi-Ju , Hsu Yi-Chiung , Hsiao Yi-Jing , Su Kang-Yi , Chen Hsuan-Yu , Lin Chien-Yu , Chen Jin-Shing , Chen Yu-Ju , Hong Qi-Sheng , Ku Wen-Hui , Wu Chih-Ying , Ho Bing-Ching , Chiang Ching-Cheng , Yang Pan-Chyr , Yu Sung-Liang
Published: April 2023

Legends include Figure S1-S13
Supplementary Figure S1-S13 from FAM198B Is Associated with Prolonged Survival and Inhibits Metastasis in Lung Adenocarcinoma via Blockage of ERK-Mediated MMP-1 Expression
Authors: Hsu Chia-Ying , Chang Gee-Chen , Chen Yi-Ju , Hsu Yi-Chiung , Hsiao Yi-Jing , Su Kang-Yi , Chen Hsuan-Yu , Lin Chien-Yu , Chen Jin-Shing , Chen Yu-Ju , Hong Qi-Sheng , Ku Wen-Hui , Wu Chih-Ying , Ho Bing-Ching , Chiang Ching-Cheng , Yang Pan-Chyr , Yu Sung-Liang
Published: April 2023

All figures of figure S1-S13
Figure S9 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
Authors: Puhr Martin , Hoefer Julia , Eigentler Andrea , Ploner Christian , Handle Florian , Schaefer Georg , Kroon Jan , Leo Angela , Heidegger Isabel , Eder Iris , Culig Zoran , Van der Pluijm Gabri , Klocker Helmut
Published: April 2023

(A) Western blot analysis of GR and AR protein expression in different passages of long-term vehicle-ctrl treated LNCaPabl cells before and during (>10 mo) cultivation in the presence of EtOH.
Figure S6 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
Authors: Puhr Martin , Hoefer Julia , Eigentler Andrea , Ploner Christian , Handle Florian , Schaefer Georg , Kroon Jan , Leo Angela , Heidegger Isabel , Eder Iris , Culig Zoran , Van der Pluijm Gabri , Klocker Helmut
Published: April 2023

(A) Proliferation and spheroid formation in DUCaP cells after 8 d of RU-486 treatment. Proliferation was assessed by ([3H]thymidine incorporation) after 6 d treatment with 10 µM RU-486.
Supplementary Appendix, Supplementary References, Supplementary Figures 1-5, Supplementary Tables 1-4 from A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
Authors: Song Jiangdian , Shi Jingyun , Dong Di , Fang Mengjie , Zhong Wenzhao , Wang Kun , Wu Ning , Huang Yanqi , Liu Zhenyu , Cheng Yue , Gan Yuncui , Zhou Yongzhao , Zhou Ping , Chen Bojiang , Liang Changhong , Liu Zaiyi , Li Weimin , Tian Jie
Published: April 2023

Supplementary Table S1. Multivariable Cox regression analysis of various clinicopathologic characteristics and the twelve-feature-based signature with progression-free survival; Supplementary Table S2. Detail of treatment of all the patients. Including the administration of TKIs, mean time of TKI therapy and chemotherapy of each department; Supplementary Table S3. Univariate association of twelve features and progression-free survival in the training dataset; Supplementary Table S4. Comparison of clinical variables between the rapid-progression subgroup and slow-progression subgroup in EGFR-TKI cases; Supplementary Figure S1. X-tile plots of the twelve selected key features; Supplementary Figure S2. Turning parameter (λ) selection in the LASSO model; Supplementary Figure S3. Stratified analysis of the signature; Supplementary Figure S4. Time-dependent ROC curves of the risk characteristics; Supplementary Figure S5. Progression probability of three different patient cohorts.
Supplementary Figure S3 from Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats
Authors: Zhang Xiyuan , Cook Katherine L. , Warri Anni , Cruz Idalia M. , Rosim Mariana , Riskin Jeffrey , Helferich William , Doerge Daniel , Clarke Robert , Hilakivi-Clarke Leena
Published: April 2023

UPR gene expression levels of mammary glands and tumors of animals before TAM treatment.
Data from A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
Authors: Song Jiangdian , Shi Jingyun , Dong Di , Fang Mengjie , Zhong Wenzhao , Wang Kun , Wu Ning , Huang Yanqi , Liu Zhenyu , Cheng Yue , Gan Yuncui , Zhou Yongzhao , Zhou Ping , Chen Bojiang , Liang Changhong , Liu Zaiyi , Li Weimin , Tian Jie
Published: April 2023

The data disclosed in this study.
All Supplementary Data from Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies In Vivo
Authors: Qin Hong , Wei Guowei , Sakamaki Ippei , Dong Zhenyuan , Cheng Wesley A. , Smith D. Lynne , Wen Feng , Sun Han , Kim Kunhwa , Cha Soungchul , Bover Laura , Neelapu Sattva S. , Kwak Larry W.
Published: April 2023

Supp. Fig. 1 Anti human BAFF-R monoclonal antibody generation and clone selection. Supp. Fig. 2 Verification that selected hybridoma clones bind MCL cells. Supp. Fig. 3 Dose-dependent binding of purified mAbs to human BAFF-R. Supp. Fig. 4 (h)BAFF-R mAbs recognized non-Hodgkin lymphoma cell lines in vitro. Supp. Fig. 5 (h)BAFF-R mAbs recognized lymphoma patient samples. Supp. Fig. 6 BAFF-R antibody specific binding was correlated to BAFF-R expression on NHL lines and primary samples. Supp. Fig. 7 Chimeric antibodies required NK cells for cytotoxicity against tumor cells. Supp. Fig. 8 Limited internalization was observed with BAFF-R mAbs. Supp. Fig. 9 BAFF-R antibody induced cytotoxicity in BAFF-R expressing lines. Supp. Fig. 10 BAFF-R mAb induced ADCC in BAFF-R expressing primary MCL samples. Supp. Fig. 11 CD20 knock out clones generated with CRISPR Supp. Fig. 12 Ibrutinib treatment failed to protected mice challenged with ibrutinib-resistant Z-138 cells. ( Supp. Fig. 13 Chimeric antibodies targeting human BAFF-R elicited in vivo therapeutic effects against Z-138 ibrutinib-resistant tumors. Supp. Fig. 14 Characterization of BAFF-R binding against normal B cells. Supp. Fig. 15 BAFF-R mAb elicited ADCC effects on normal human B cells.
Supplementary Figures 1-3 from STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner
Authors: Sun Shanshan , Wu Yansheng , Guo Wenyu , Yu Feng , Kong Lingping , Ren Yu , Wang Yu , Yao Xiaofeng , Jing Chao , Zhang Chao , Liu Mingyang , Zhang Yuqing , Zhao Minghui , Li Zhaoqing , Wu Chuanqiang , Qiao Yu , Yang Jingxuan , Wang Xudong , Zhang Lun , Li Min , Zhou Xuan
Published: April 2023

Supplementary Figure 1. HNSCC exerts robust activity of the STAT3/EZH2 and PI3K/AKT signaling axes, which were related to growth and drug sensitivity.; Supplementary Figure 2. TCGA HNSCC RNA-seq datasets analysis.; Supplementary Figure 3. Sequence of STAT3 binding sites in HOTAIR gene promoter.
Supplementary Figure 4 from Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response
Authors: Muckenhuber Alexander , Berger Anne Katrin , Schlitter Anna Melissa , Steiger Katja , Konukiewitz Björn , Trumpp Andreas , Eils Roland , Werner Jens , Friess Helmut , Esposito Irene , Klöppel Günter , Ceyhan Güralp O. , Jesinghaus Moritz , Denkert Carsten , Bahra Marcus , Stenzinger Albrecht , Sprick Martin R. , Jäger Dirk , Springfeld Christoph , Weichert Wilko
Published: April 2023

Differences between molecular subtypes with regard to initial tumor control irrespective of chemotherapeutic regimen (p-value 0.033). Y-axis is representing total patient count.
Figure S1 from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
Authors: Xochelli Aliki , Baliakas Panagiotis , Kavakiotis Ioannis , Agathangelidis Andreas , Sutton Lesley-Ann , Minga Eva , Ntoufa Stavroula , Tausch Eugen , Yan Xiao-Jie , Shanafelt Tait , Plevova Karla , Boudjogra Myriam , Rossi Davide , Davis Zadie , Navarro Alba , Sandberg Yorick , Vojdeman Fie Juhl , Scarfo Lydia , Stavroyianni Niki , Sudarikov Andrey , Veronese Silvio , Tzenou Tatiana , Karan-Djurasevic Teodora , Catherwood Mark , Kienle Dirk , Chatzouli Maria , Facco Monica , Bahlo Jasmin , Pott Christiane , Pedersen Lone Bredo , Mansouri Larry , Smedby Karin E. , Chu Charles C. , Giudicelli Véronique , Lefranc Marie-Paule , Panagiotidis Panagiotis , Juliusson Gunnar , Anagnostopoulos Achilles , Vlahavas Ioannis , Antic Darko , Trentin Livio , Montillo Marco , Niemann Carsten , Döhner Hartmut , Langerak Anton W. , Pospisilova Sarka , Hallek Michael , Campo Elias , Chiorazzi Nicholas , Maglaveras Nikos , Oscier David , Gaidano Gianluca , Jelinek Diane F. , Stilgenbauer Stephan , Chouvarda Ioanna , Darzentas Nikos , Belessi Chrysoula , Davi Frederic , Hadzidimitriou Anastasia , Rosenquist Richard , Ghia Paolo , Stamatopoulos Kostas
Published: April 2023

Distribution of IGHV4-34 CLL according to IGHV mutational status and subset membership.
Supplementary Table 1-3, Supplementary Figure Legend from A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Authors: Yau Thomas C.C. , Lencioni Riccardo , Sukeepaisarnjaroen Wattana , Chao Yee , Yen Chia-Jui , Lausoontornsiri Wirote , Chen Pei-Jer , Sanpajit Theeranun , Camp Aaron , Cox Donna S. , Gagnon Robert C. , Liu Yuan , Raffensperger Kristen E. , Kulkarni Diptee A. , Kallender Howard , Ottesen Lone Harild , Poon Ronnie T.P. , Bottaro Donald P.
Published: April 2023

Table S1: Summary of pharmacokinetic parameters (days 1 and 15); Table S2: Significant changes in circulating biomarkers from baseline; Table S3: Multivariate models for selected covariates, Overall Survival.
Suppl Table 2 from The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA
Authors: Parpart-Li Sonya , Bartlett Bjarne , Popoli Maria , Adleff Vilmos , Tucker Laura , Steinberg Rebecca , Georgiadis Andrew , Phallen Jill , Brahmer Julie , Azad Nilo , Browner Ilene , Laheru Daniel , Velculescu Victor E. , Sausen Mark , Diaz Luis A.
Published: April 2023

Observed genome equivalents, wild-type DNA fragments, mutant DNA fragments, and mutant allele frequency in K2EDTA and Streck{trade mark, serif} BCT tubes at room temperature.
Supplementary Methods, Supplementary Figure Legends, Supplementary Table from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Authors: Kwak Jae-Yong , Kim Sung-Hyun , Oh Suk Joong , Zang Dae Young , Kim Hawk , Kim Jeong-A , Do Young Rok , Kim Hyeoung Joon , Park Joon Seong , Choi Chul Won , Lee Won Sik , Mun Yeung-Chul , Kong Jee Hyun , Chung Joo Seop , Shin Ho-Jin , Kim Dae-Young , Park Jinny , Jung Chul Won , Bunworasate Udomsak , Comia Narcisa Sonia , Jootar Saengsuree , Reksodiputro Arry Harryanto , Caguioa Priscilla B. , Lee Sung-Eun , Kim Dong-Wook
Published: April 2023

Supplementary Methods, Supplementary Figure Legends, Supplementary Table
Supplementary Figure S6 from Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells
Authors: Katsha Ahmed , Wang Lihong , Arras Janet , Omar Omar M. , Ecsedy Jeffrey , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

Supp Fig 6
Supplementary Figure 1 from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Authors: Kwak Jae-Yong , Kim Sung-Hyun , Oh Suk Joong , Zang Dae Young , Kim Hawk , Kim Jeong-A , Do Young Rok , Kim Hyeoung Joon , Park Joon Seong , Choi Chul Won , Lee Won Sik , Mun Yeung-Chul , Kong Jee Hyun , Chung Joo Seop , Shin Ho-Jin , Kim Dae-Young , Park Jinny , Jung Chul Won , Bunworasate Udomsak , Comia Narcisa Sonia , Jootar Saengsuree , Reksodiputro Arry Harryanto , Caguioa Priscilla B. , Lee Sung-Eun , Kim Dong-Wook
Published: April 2023

Achievement of MMR by 12 months according to 3-month EMR (< 10% of BCR-ABL1IS).EMR at 3 months.
Supplementary Figure S3 from Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells
Authors: Katsha Ahmed , Wang Lihong , Arras Janet , Omar Omar M. , Ecsedy Jeffrey , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

Supp Fig 3
Supplementary Figure S1 from Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells
Authors: Katsha Ahmed , Wang Lihong , Arras Janet , Omar Omar M. , Ecsedy Jeffrey , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

Supp Fig 1
Supplementary Figure 7 from The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB
Authors: Garcia-Heredia Jose Manuel , Lucena-Cacace Antonio , Verdugo-Sivianes Eva M. , Pérez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure 7. IC50 of human cell lines overexpressing MAP17 treated with DAPT. Cells were treated for 96 hours with decreasing amount of DAPT. IC50 values: AA EV: 7 {plus minus} 3.6 ÂµM; AA M17: 9.2 {plus minus} 1.7 ÂµM; Calu3 scr: 7.8 {plus minus} 1.3 ÂµM; Calu3 shM17: 1.6 {plus minus} 1.7 ÂµM; T47D EV: 164.8 {plus minus} 32.22 ÂµM; T47D M17: 2.2 {plus minus} 7.3 ÂµM
Supplementary Figure 6 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
Authors: Soler Adriana , Figueiredo Ana M. , Castel Pau , Martin Laura , Monelli Erika , Angulo-Urarte Ana , Milà-Guasch Maria , Viñals Francesc , Baselga Jose , Casanovas Oriol , Graupera Mariona
Published: April 2023

Effects of GDC-0326 in EC and Î²TC cells ; Supplemental Figure 6 Legend
Supplementary Figure 5 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
Authors: Soler Adriana , Figueiredo Ana M. , Castel Pau , Martin Laura , Monelli Erika , Angulo-Urarte Ana , Milà-Guasch Maria , Viñals Francesc , Baselga Jose , Casanovas Oriol , Graupera Mariona
Published: April 2023

Assessment of cell proliferation upon inhibition of p110Î± ; Supplemental Figure 5 Legend
Supplementary Figure 3 from Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
Authors: Reusch Uwe , Harrington Kimberly H. , Gudgeon Chelsea J. , Fucek Ivica , Ellwanger Kristina , Weichel Michael , Knackmuss Stefan H.J. , Zhukovsky Eugene A. , Fox Judith A. , Kunkel Lori A. , Guenot Jeanmarie , Walter Roland B.
Published: April 2023

Correlation of CD3 and CD33 affinity with EC50 in T-cell proliferation assays. Data points from proliferation assays shown in Supplemental Figure 2 were plotted as a function of KD on T-cells or CD33+ cells.
Supplementary Figure 2 from Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
Authors: Reusch Uwe , Harrington Kimberly H. , Gudgeon Chelsea J. , Fucek Ivica , Ellwanger Kristina , Weichel Michael , Knackmuss Stefan H.J. , Zhukovsky Eugene A. , Fox Judith A. , Kunkel Lori A. , Guenot Jeanmarie , Walter Roland B.
Published: April 2023

Proliferation assays with PBMCs and T-cell cultures. Incorporation of BrdU in proliferating cells over a four-day incubation quantified using a BrdU ELISA as a function of increasing TandAb concentration.
Supplementary Figure 1 from Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
Authors: Reusch Uwe , Harrington Kimberly H. , Gudgeon Chelsea J. , Fucek Ivica , Ellwanger Kristina , Weichel Michael , Knackmuss Stefan H.J. , Zhukovsky Eugene A. , Fox Judith A. , Kunkel Lori A. , Guenot Jeanmarie , Walter Roland B.
Published: April 2023

Flow cytometry analysis of for AML cell cytotoxicity determinations. Flow cytometry analysis of cells from one healthy donor T-cell aliquot and one representative AML cell line (HL- 60) and primary AML specimen (AMP002) illustrating the strategy pursued to determine antibody-induced cytotoxicity.
Supplementary figure 4 from Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Authors: Wang Chun-Meng , Wu Zhi-Qiang , Wang Yao , Guo Ye-Lei , Dai Han-Ren , Wang Xiao-Hui , Li Xiang , Zhang Ya-Jing , Zhang Wen-Ying , Chen Mei-Xia , Zhang Yan , Feng Kai-Chao , Liu Yang , Li Su-Xia , Yang Qing-Ming , Han Wei-Dong
Published: April 2023

Progression-free survival by Kaplan-Meier method.
Supplementary data [S-5] from Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients
Authors: Wang Rui , Wang Jing , Gao Ge , Hu Juan , Jiang Yuanyuan , Zhao Zhenlong , Zhang Xiaodong , Zhang Yu-Dong , Wang Xiaoying
Published: April 2023

Risk Factors of the Progression of PCa Analyzed by Cox Proportional Hazard Regression Models
Supplementary figure 3 from Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Authors: Wang Chun-Meng , Wu Zhi-Qiang , Wang Yao , Guo Ye-Lei , Dai Han-Ren , Wang Xiao-Hui , Li Xiang , Zhang Ya-Jing , Zhang Wen-Ying , Chen Mei-Xia , Zhang Yan , Feng Kai-Chao , Liu Yang , Li Su-Xia , Yang Qing-Ming , Han Wei-Dong
Published: April 2023

The adverse event after the CART-30 cell infusion.
Figure S2 from Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib
Authors: Wongchenko Matthew J. , McArthur Grant A. , Dréno Brigitte , Larkin James , Ascierto Paolo A. , Sosman Jeffrey , Andries Luc , Kockx Mark , Hurst Stephen D. , Caro Ivor , Rooney Isabelle , Hegde Priti S. , Molinero Luciana , Yue Huibin , Chang Ilsung , Amler Lukas , Yan Yibing , Ribas Antoni
Published: April 2023

Supplementary Figure S2. Filtering scheme to identify genes significantly associated with PFS.
Supplemental Figure 2 from Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma
Authors: Hansson Jennifer , Lindgren David , Nilsson Helén , Johansson Elinn , Johansson Martin , Gustavsson Lena , Axelson Håkan
Published: April 2023

SLC6A3 expression in relation to molecular, clinical and histopathological parameters in the TCGA data.
Supplementary Figure 3 from Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer
Authors: De Robertis Mariangela , Loiacono Luisa , Fusilli Caterina , Poeta Maria Luana , Mazza Tommaso , Sanchez Massimo , Marchionni Luigi , Signori Emanuela , Lamorte Giuseppe , Vescovi Angelo Luigi , Garcia-Foncillas Jesus , Fazio Vito Michele
Published: April 2023

Supplementary Figure 3 - Clinical characteristics of EphA2high and EphA2low patients in cohort 1 to 6
Figure S4 from Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans
Authors: Mitchell Khadijah A. , Zingone Adriana , Toulabi Leila , Boeckelman Jacob , Ryan Bríd M.
Published: April 2023

Unique pathway enrichment in lung tumors from AAs and EAs.
Supplementary Figure 1 from Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone
Authors: Rathkopf Dana E. , Antonarakis Emmanuel S. , Shore Neal D. , Tutrone Ronald F. , Alumkal Joshi J. , Ryan Charles J. , Saleh Mansoor , Hauke Ralph J. , Bandekar Rajesh , Maneval Edna Chow , de Boer Carla J. , Yu Margaret K. , Scher Howard I.
Published: April 2023

Study design (A) and patient disposition (B); data cutoff December 31, 2014.
Figure S1 from Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma
Authors: Byron Sara A. , Tran Nhan L. , Halperin Rebecca F. , Phillips Joanna J. , Kuhn John G. , de Groot John F. , Colman Howard , Ligon Keith L. , Wen Patrick Y. , Cloughesy Timothy F. , Mellinghoff Ingo K. , Butowski Nicholas A. , Taylor Jennie W. , Clarke Jennifer L. , Chang Susan M. , Berger Mitchel S. , Molinaro Annette M. , Maggiora Gerald M. , Peng Sen , Nasser Sara , Liang Winnie S. , Trent Jeffrey M. , Berens Michael E. , Carpten John D. , Craig David W. , Prados Michael D.
Published: April 2023

Study Workflow Diagram. Key steps in the study are outlined, including the number of patients at each stage. BEV: bevacizumab.
Supplementary Figures 1-5, Supplementary Tables 1-2 from B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes
Authors: Altan Mehmet , Pelekanou Vasiliki , Schalper Kurt A. , Toki Maria , Gaule Patricia , Syrigos Konstantinos , Herbst Roy S. , Rimm David L.
Published: April 2023

Table 1. Clinico-pathologic features of the Non-small cell lung cancer cohorts (Cohort A, B and C); Table 2. Cox regression model with clinicopathologic features, tumor B7-H3, B7-H4 and PD-L1 protein expression risk ratios for 3 cohorts; Figure 1. B7-H3 antibody validation; Figure 2. B7-H4 antibody validation; Figure 3. B7-H3 tumor and stromal protein expression regression, staining examples; Figure 4. Co-expression co-localization of B7-H3 and PD-L1; Figure 5. Additional images for Co-expression co-localization of B7-H3 and B7-H4
Supplementary Materials and Methods from Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
Authors: Yang Yu Chi , Banuelos Carmen Adriana , Mawji Nasrin R. , Wang Jun , Kato Minoru , Haile Simon , McEwan Iain J. , Plymate Stephen , Sadar Marianne D.
Published: April 2023

The Supplementary Materials and Methods contain information for the reagents and plasmids and procedures for experiments in the manuscript.
Supplementary Figure 3 from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Authors: Pikman Yana , Alexe Gabriela , Roti Giovanni , Conway Amy Saur , Furman Andrew , Lee Emily S. , Place Andrew E. , Kim Sunkyu , Saran Chitra , Modiste Rebecca , Weinstock David M. , Harris Marian , Kung Andrew L. , Silverman Lewis B. , Stegmaier Kimberly
Published: April 2023

LEE011 is synergistic with dexamethasone, prednisolone, and everolimus.
Supplementary Figure S3 from In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated Apoptosis
Authors: Fornari Francesca , Pollutri Daniela , Patrizi Clarissa , La Bella Tiziana , Marinelli Sara , Casadei Gardini Andrea , Marisi Giorgia , Baron Toaldo Marco , Baglioni Michele , Salvatore Veronica , Callegari Elisa , Baldassarre Maurizio , Galassi Marzia , Giovannini Catia , Cescon Matteo , Ravaioli Matteo , Negrini Massimo , Bolondi Luigi , Gramantieri Laura
Published: April 2023

Figure S3. (A-C) Box plot graphs of AFP, MYC and CK19 mRNAs expression in DENtreated rats following Sorafenib administration.
Supplemental Figure 4 from Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma
Authors: Lawson Keith A. , Mostafa Ahmed A. , Shi Zhong Qiao , Spurrell Jason , Chen Wenqian , Kawakami Jun , Gratton Kathy , Thakur Satbir , Morris Donald G.
Published: April 2023

CD8+ and CD4+ cell depletion confirmation study.
Supplementary Figure Legend from Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies
Authors: Kelly Kevin , Mejia Alex , Suhasini Avvaru N. , Lin An-Ping , Kuhn John , Karnad Anand B. , Weitman Steven , Aguiar Ricardo C.T.
Published: April 2023

Supplementary Figure Legend
Table S1 from In Vivo Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development
Authors: Jaworski Felipe M. , Gentilini Lucas D. , Gueron Geraldine , Meiss Roberto P. , Ortiz Emiliano G. , Berguer Paula M. , Ahmed Asif , Navone Nora , Rabinovich Gabriel A. , Compagno Daniel , Laderach Diego J. , Vazquez Elba S.
Published: April 2023

List of the primers used in qPCR analyses carried out in this study.
Supplementary Table S2 from An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma
Authors: Citron Francesca , Armenia Joshua , Franchin Giovanni , Polesel Jerry , Talamini Renato , D'Andrea Sara , Sulfaro Sandro , Croce Carlo M. , Klement William , Otasek David , Pastrello Chiara , Tokar Tomas , Jurisica Igor , French Deborah , Bomben Riccardo , Vaccher Emanuela , Serraino Diego , Belletti Barbara , Vecchione Andrea , Barzan Luigi , Baldassarre Gustavo
Published: April 2023

Supplementary Table S2: Pathway enrichment analyses of miRs putative targets.
Supplementary Figure 2 from The Interplay Between Neutrophils and CD8+ T Cells Improves Survival in Human Colorectal Cancer
Authors: Governa Valeria , Trella Emanuele , Mele Valentina , Tornillo Luigi , Amicarella Francesca , Cremonesi Eleonora , Muraro Manuele Giuseppe , Xu Hui , Droeser Raoul , Däster Silvio R. , Bolli Martin , Rosso Raffaele , Oertli Daniel , Eppenberger-Castori Serenella , Terracciano Luigi M. , Iezzi Giandomenica , Spagnoli Giulio C.
Published: April 2023

Co-culture with PBNs does not impact on growth of CRC cell lines. (A) PBNs from healthy donors (HD) were co-cultured with 6 different CRC cell lines at a CRC: PBN ratio 1: 20, as described in â€œmaterials and methodsâ€�. After 72h, tumour cells proliferation was measured by 3Hthymidine incorporation. Similar experiments, using LS180 as target cells were also performed by utilizing PBN from patients with CRC (B) and PBN from HD, untreated or following one hour treatment with IFN-Î³ (1ng/ml), fMLP (50Î¼M) or both (C).
Supplementary Figure S2 from A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients
Authors: van Vlodrop Iris J.H. , Joosten Sophie C. , De Meyer Tim , Smits Kim M. , Van Neste Leander , Melotte Veerle , Baldewijns Marcella M.L.L. , Schouten Leo J. , van den Brandt Piet A. , Jeschke Jana , Yi Joo Mi , Schuebel Kornel E. , Ahuja Nita , Herman James G. , Aarts Maureen J. , Bosman Fred T. , Van Criekinge Wim , van Engeland Manon
Published: April 2023

Supplementary Figure S2. Validation of up-regulation of gene expression after demethylation with DAC by qRT-PCR for 22 genes. Relative mRNA expression of 22 genes analyzed by qRT-PCR in ccRCC cell lines SKRC1, SKRC52 and SKRC59 treated with either mock or 5ÃŽÂ¼m 5-aza-2'-deoxycytidine (DAC) for 96 hours. Expression levels were analyzed in triplo unless stated otherwise. Error bars indicate the standard error of the mean. * in duplo; ** single values due to technical failure; *** no expression in SKRC1 and SKRC59.
Supplementary Figure S1 from A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients
Authors: van Vlodrop Iris J.H. , Joosten Sophie C. , De Meyer Tim , Smits Kim M. , Van Neste Leander , Melotte Veerle , Baldewijns Marcella M.L.L. , Schouten Leo J. , van den Brandt Piet A. , Jeschke Jana , Yi Joo Mi , Schuebel Kornel E. , Ahuja Nita , Herman James G. , Aarts Maureen J. , Bosman Fred T. , Van Criekinge Wim , van Engeland Manon
Published: April 2023

Supplementary Figure S1. Methylation analysis of GREM1, LAD1, NEFH and NEURL by methylation-specific PCR (MSP) in the hospital- and population-based series and in the TCGA series. A. Schematic representation of the CpG island promoter region of the four genes with the location of the primers used for MSP (indicated by horizontal arrows) relative to the probes used in the TCGA analyses (indicated by a vertical arrow) in this study. Vertical lines represent the location of CpG dinucleotides, the black box indicates the first exon, and the grey horizontal line represents the promoter CpG island. TSS: transcription start site. B. Histograms of the beta-values of the selected probes for GREM1, LAD1, NEFH and NEURL. The vertical grey line indicates the beta-value cut-off for each probe that was used in the TCGA analyses.
NACT Supplementary Tables - revised from Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy
Authors: Lo Charlotte S. , Sanii Sanaz , Kroeger David R. , Milne Katy , Talhouk Aline , Chiu Derek S. , Rahimi Kurosh , Shaw Patricia A. , Clarke Blaise A. , Nelson Brad H.
Published: April 2023

Supplementary Table S1. Antibody dilutions used in single-color IHC. Supplementary Table S2. Antibody dilutions and chromogens in multi-color IHC. Supplementary Table S3. Additional patient characteristics of cohort A. Supplementary Table S4. Immune cell densities and absolute counts in matched pre- and post-NACT tumor samples with multiple comparisons (n=26).
Suppl Information from Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant
Authors: Hsu Pei-Yin , Wu Victoria Shang , Kanaya Noriko , Petrossian Karineh , Hsu Hang-Kai , Nguyen Duc , Schmolze Daniel , Kai Masaya , Liu Chun-Yu , Lu Hannah , Chu Peiguo , Vito Courtney A. , Kruper Laura , Mortimer Joanne , Chen Shiuan
Published: April 2023

Suppl Information Table S1. Clinical characteristics of COH-SC1 and COH-SC31 PDXs
Suppl Figure Legends from Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant
Authors: Hsu Pei-Yin , Wu Victoria Shang , Kanaya Noriko , Petrossian Karineh , Hsu Hang-Kai , Nguyen Duc , Schmolze Daniel , Kai Masaya , Liu Chun-Yu , Lu Hannah , Chu Peiguo , Vito Courtney A. , Kruper Laura , Mortimer Joanne , Chen Shiuan
Published: April 2023

Suppl Figure Legends
Supplemental information from CD31 Expression Determines Redox Status and Chemoresistance in Human Angiosarcomas
Authors: Venkataramani Vivek , Küffer Stefan , Cheung Kenneth C.P. , Jiang Xuejun , Trümper Lorenz , Wulf Gerald G. , Ströbel Philipp
Published: April 2023

Supplemental Figure legends
Supplementary Tables 1-11 from Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer
Authors: Liang Qiaoyi , Chiu Jonathan , Chen Yingxuan , Huang Yanqin , Higashimori Akira , Fang Jingyuan , Brim Hassan , Ashktorab Hassan , Ng Siew Chien , Ng Simon Siu Man , Zheng Shu , Chan Francis Ka Leung , Sung Joseph Jao Yiu , Yu Jun
Published: April 2023

Supplementary Table S1. Clinical characteristics of healthy subjects and colorectal cancer patients; Supplementary Table S2. Bacterial marker candidates identified by metagenome sequencing; Supplementary Table S3. Primers and probes used in this study; Supplementary Table S4. Abundances of m1704941 (gene maker level, 99.13% identity) and F. nucleatum (species level) in fecal samples of CRC patients by metagenome sequencing; Supplementary Table S5. Abundances of bacterial candidates in fecal samples of CRC patients and healthy control subjects; Supplementary Table S6. Bivariate correlation analysis showing the correlation between bacterial candidates and CRC patients; Supplementary Table S7. The occurrence rates of bacterial candidates in fecal samples of CRC patients and healthy control subjects; Supplementary Table S8. Pairwise comparison of ROC curves; Supplementary Table S9. Correlations of bacterial abundance, FIT with CRC diagnosis and staging; Supplementary Table S11. Combining bacterial markers and FIT in diagnosing CRC.
Supplementary Figure S3 from A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
Authors: Salvucci Manuela , Würstle Maximilian L. , Morgan Clare , Curry Sarah , Cremona Mattia , Lindner Andreas U. , Bacon Orna , Resler Alexa J. , Murphy Áine C. , O'Byrne Robert , Flanagan Lorna , Dasgupta Sonali , Rice Nadege , Pilati Camilla , Zink Elisabeth , Schöller Lisa M. , Toomey Sinead , Lawler Mark , Johnston Patrick G. , Wilson Richard , Camilleri-Broët Sophie , Salto-Tellez Manuel , McNamara Deborah A. , Kay Elaine W. , Laurent-Puig Pierre , Van Schaeybroeck Sandra , Hennessy Bryan T. , Longley Daniel B. , Rehm Markus , Prehn Jochen H.M.
Published: April 2023

Impact of each predictor included in the Random Forest classifier on the probability of recurrence alone and in combination with the others.